Folic Acid as the Adjuvant Therapy for Chronic Schizophrenia: A Comprehensive Study on Glutathione Reductase

Innawati Jusup; Hery Murtantyo; Sri Woroasih; Alifiati Fitrikasari

doi:10.3889/oamjms.2022.9308

Authors

Innawati Jusup Psychiatric Study Program, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
Hery Murtantyo Psychiatric Study Program, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
Sri Woroasih Department of Psychiatry, Mental Hospital Dr. Aminogondohutomo, Semarang, Indonesia
Alifiati Fitrikasari Psychiatric Study Program, Faculty of Medicine, Diponegoro University, Semarang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9308

Keywords:

Chronic schizophrenia, Folic acid, Glutathione reductase levels, PANSS score

Abstract

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Stepnicki P, Magda Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8):1-29. https://doi.org/10.3390/molecules23082087 PMid:30127324 DOI: https://doi.org/10.3390/molecules23082087

Kementrian Kesehatan Republik Indonesia. Persebaran prevalensi skizofrenia/psikosis di Indonesia. Available from: https://pusdatin.kemkes.go.id/download.php%3Ffile%3Ddownload/pusdatin/infodatin/InfoDatin-Kesehatan-Jiwa.pdf+&cd=5&hl=id&ct=clnk&gl=id [Last accessed on 2019 Oct 08].

Fung L, Hardan A. Oxidative Stress in Psychiatric Disorders. Berlin: Springer; 2019. p. 1-20.

Padmanabhan P. A review on biochemical aspects of schizophrenia. Int J Cur Res Rev. 2017;9(21):1-4.

Emiliani FE, Sedlack TW, Sawa A. Oxidative stress and schizophrenia: Recent breakthroughs from an old story. Curr Opin Psychiatry. 2014;27(3):185-90. https://doi.org/10.1097/YCO.0000000000000054 PMid:24613987 DOI: https://doi.org/10.1097/YCO.0000000000000054

Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14(1):123-30. https://doi.org/10.1017/S1461145710000805 PMid:20633320 DOI: https://doi.org/10.1017/S1461145710000805

Wang D, Zhai JX, Liu DW. Serum folate levels in schizophrenia: A meta-analysis. J Psychiatry Res. 2015;235:83-9. https://doi.org/10.1016/j.psychres.2015.11.045 PMid:26652840 DOI: https://doi.org/10.1016/j.psychres.2015.11.045

Azzini E, Ruggeri S, Polito A. Homocysteine: Its possible emerging role in at-risk population groups. Int J Mol Sci. 2020;21(4):1-27. https://doi.org/10.3390/ijms21041421 PMid:32093165 DOI: https://doi.org/10.3390/ijms21041421

Koga M, Serritella AV, Sawa A, Sedlack TW. Implications for reactive oxygen species in schizophrenia pathogenesis. J Schizophrenia Res. 2016;176(1):52-71. https://doi.org/10.1016/j.schres.2015.06.022 PMid:26589391 DOI: https://doi.org/10.1016/j.schres.2015.06.022

Nucifora LG, Tanaka T, Hayes LN, Kim M, Lee BJ, Matsuda T, et al. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl Psychiatry. 2017;7(8):e1215. https://doi.org/10.1038/tp.2017.178 PMid:28892069 DOI: https://doi.org/10.1038/tp.2017.178

Sakuma K, Mastunaga S, Nomura I, Okuya M, Kishi T, Iwata N. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: A systematic review and meta-analysis. J Psychopharmacol. 2018;235(8):2303-14. https://doi.org/10.1007/s00213-018-4926-4 PMid:29785555 DOI: https://doi.org/10.1007/s00213-018-4926-4

Koujalgi SR, Patil SR. Comparison of demographic profile of patient with schizophrenia and depression. J Sci Soc. 2013;40:20-4. DOI: https://doi.org/10.4103/0974-5009.109686

Sommer IE, Tiihonen J, van Mourik A, Tanskanen A, Taipale H. The clinical course of schizophrenia in women and men, a nation-wide cohort study. NPJ Schizophr. 2020;6(1):12. https://doi.org/10.1038/s41537-020-0102-z PMid:32358572 DOI: https://doi.org/10.1038/s41537-020-0102-z

Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first- episode psychosis: A comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198. https://doi.org/10.1155/2012/916198 PMid:22966451 DOI: https://doi.org/10.1155/2012/916198

Ezeme MS, Uwakwe R, Ndukuba AC, Igwe MN, Odinka PC, Amadi K, et al. Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria. Afri Health Sci. 2016;16(4):1036-44. https://doi.org/10.4314/ahs.v16i4.21 PMid:28479897 DOI: https://doi.org/10.4314/ahs.v16i4.21

Adebiyi MO, Mosaku SK, Irinoye OO, Oyelade OO. Sociodemographic and clinical factors associated with relapse in mental illness. Int J Afr Nurs Sci. 2018;8:149-53. DOI: https://doi.org/10.1016/j.ijans.2018.05.007

Adi AC, Margono HM, Handajani R. Relationship between Duration of Illness and Onset with PANSS and Interleukin-6 in Schizophrenia. J Brain Res. 2019;2:109.

Susilowati N, Hanim D, Dewi YL. Body mass index of schizophrenic patients with combined antipsychotic therapy. Int J Nutr Sci. 2020;5(1):7-12.

Isuru A, Rajasuriya M. Tobacco smoking and schizophrenia: re-examining the evidence. BJPsych Adv. 2019;25:363-72. DOI: https://doi.org/10.1192/bja.2019.33

Aleksandrovа LA, Subbotina TF, Zhloba AA. The relationship of folate deficiency, hyperhomocysteinemia and glutathione metabolism in hypertensive patients. Arterial Hypertens. 2020;26(6):656-64. DOI: https://doi.org/10.18705/1607-419X-2020-26-6-656-664

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of Folate Plus Vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70(5):481-9. https://doi.org/10.1001/jamapsychiatry.2013.900 PMid:23467813 DOI: https://doi.org/10.1001/jamapsychiatry.2013.900

Song X, Fan X, Li X, Kennedy D, Pang L, Quan M, et al. Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophrenia Res. 2014;159(1):51-5. https://doi.org/10.1016/j.schres.2014.07.033 PMid:25128453 DOI: https://doi.org/10.1016/j.schres.2014.07.033

Moustafa AA, Hewedi D, Eissa AM, Frydecka D, Misiak B. Homocysteine levels in schizophrenia and affective disorders focus on cognition. Front Behav Neurosci. 2014;8:343. https://doi.org/10.3389/fnbeh.2014.00343 PMid:25339876 DOI: https://doi.org/10.3389/fnbeh.2014.00343

Sugden C. One-carbon metabolism in psychiatric illness. Nutr Res Rev. 2006;19(1):117-36. https://doi.org/10.1079/NRR2006119 PMid:19079880 DOI: https://doi.org/10.1079/NRR2006119

Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP. Oxidative stress-related mechanisms in schizophrenia pathogenesis and new treatment perspectives. Oxid Med Cell Longev. 2021;2021:8881770. https://doi.org/10.1155/2021/8881770 PMid:33552387 DOI: https://doi.org/10.1155/2021/8881770

Langbein K, Hesse J, Gussew A, Milleit B, Lavoie S, Amminger GP, et al. Disturbed glutathione antioxidative defense is associated with structural brain changes in neuroleptic-naïve first-episode psychosis patients. Prostaglandins, Leukotrienes Essent Fatty Acids. 2017;136:103-10. https://doi.org/10.1016/j.plefa.2017.10.005 PMid:29111383 DOI: https://doi.org/10.1016/j.plefa.2017.10.005

Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz E, Ho NF, et al. Biochemical, physiologic, and clinical effects of l-methylfolate in schizophrenia: A randomized controlled trial. Mol Psychiatry. 2018;23(2):316-22. https://doi.org/10.1038/mp.2017.41 PMid:28289280 DOI: https://doi.org/10.1038/mp.2017.41